The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2, first-in-human, open-label, dose-escalation and -expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8+ regulatory T cells, in adult patients with locally advanced or metastatic solid tumors.
 
Anthony Olszanski
Consulting or Advisory Role - Anaveon; Bristol-Myers Squibb; IO Biotech; Replimune; Signatera
Research Funding - Anaveon (Inst); Antengene (Inst); Clasp (Inst); Clasp (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Lantern Pharma (Inst); Lilly (Inst); Normunity (Inst); Regeneron (Inst); Replimune (Inst); Shionogi (Inst); Solve (Inst); Tagworks (Inst); Takeda (Inst); Viewpoint Molecular Targeting (Inst)
 
Drew Rasco
Research Funding - 23andMe (Inst); Adcentrx Therapeutics (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Aulos Bioscience (Inst); Avenzo (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Compugen (Inst); Context Therapeutics (Inst); Corcept Therapeutics (Inst); Cullinan Oncology (Inst); Eikon Therapeutics (Inst); Flare Therapeutics (Inst); FoRx Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Johnson & Johnson/Janssen (Inst); Macrogenics (Inst); MediLink Therapeutics (Inst); Multitude Therapeutics (Inst); OnCusp Therapeutics (Inst); PAQ Therapeutics (Inst); Plexium (Inst); PureTech (Inst); Rondo (Inst); Takeda (Inst); TD2 (Inst); Whitehawk (Inst); Whitehawk (Inst)
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Pfizer; Regeneron; Vertex
Consulting or Advisory Role - AADi; Enlaza Therapeutics; Pliant; Whitehawk Therapeutics
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Arcus Biosciences (Inst); Artios (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Boundless Bio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Circle Pharma (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Day One Biopharmaceuticals (Inst); Debiopharm Group (Inst); Deciphera (Inst); EvolveImmune Therapeutics (Inst); Exelixis (Inst); Exscientia (Inst); FoRx Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Halda Therapeutics (Inst); Helsinn Therapeutics (Inst); Iambic Therapeutics (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Ipsen (Inst); Johnson & Johnson/Janssen (Inst); Johnson & Johnson/Janssen (Inst); KLUS Pharma (Inst); Kumquat Biosciences (Inst); Macrogenics (Inst); Mbrace Therapeutics (Inst); MediLink Therapeutics (Inst); Menarini Group (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mitsubishi Tanabe Pharma (Inst); Moderna Therapeutics (Inst); Monte Rosa Therapeutics (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Olema Pharmaceuticals (Inst); Opna Bio (Inst); Pfizer (Inst); Pliant (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Third Arc Bio (Inst); Treeline Biosciences (Inst); VelaVigo Bio (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)
 
Michael Song
No Relationships to Disclose
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); Curio Science (Inst); CytomX Therapeutics (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Pfizer (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Cesar Perez
Consulting or Advisory Role - BeiGene; Ipsen; Pfizer
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Avenzo Therapeutics (Inst); Avenzo Therapeutics (Inst); BeiGene (Inst); Coherent Biopharma (Inst); Coherus Biosciences (Inst); Compass Therapeutics (Inst); Corvus Pharmaceuticals (Inst); DualityBio (Inst); Elevation Oncology (Inst); Exelixis (Inst); Genentech (Inst); Kura Oncology (Inst); Loxo/Lilly (Inst); Menarini (Inst); Merus (Inst); Mirati Therapeutics (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Tallac Therapeutics (Inst); Torl Biotherapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; Amgen; AstraZeneca; Tempus
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
 
Rachel Sanborn
Honoraria - Curio Science; Illumina; OncLive/MJH Life Sciences; Targeted Oncology
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Daiichi Sankyo; G1 Therapeutics; GE Healthcare; Gilead Sciences; GlaxoSmithKline; IDEOlogy Health; Illumina; InhibRx; Janssen Oncology; Johnson & Johnson/Janssen; Lilly; Natera; OSE Immunotherapeutics; Pfizer; Rigel; Sanofi/Aventis
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Merck
Travel, Accommodations, Expenses - Hotspot Therapeutics
 
M Wasif Saif
Consulting or Advisory Role - Genentech
Research Funding - Astellas Pharma; BeiGene; Endevica Bio (Inst); GlaxoSmithKline; IDEAYA Biosciences (Inst); Marengo Therapeutics; OBI Pharma; Systimmune; Takeda (Inst); Teva; TORL Biotherapeutics; Tyra Biosciences; Yiviva (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Douglas Adkins
Consulting or Advisory Role - Adcendo; Adlai Nortye; AstraZeneca; Boehringer Ingelheim; CUE Biopharma; Genmab/Seattle Genetics; GlaxoSmithKline; Immunitas; InhibRx; Johnson & Johnson/Janssen; Kura Oncology; Merck; Merus; Purple Biotech; Pyxis; Regeneron; Tubulis GmbH
Research Funding - Adlai Nortye (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); Coherus Biosciences (Inst); CUE Biopharma (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immutep (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Rgenta (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tempus (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst); Xilio Therapeutics (Inst)
 
Vincent Lam
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Iovance Biotherapeutics; Lilly; Nuvation Bio; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); BioNTech SE (Inst); BMS (Inst); Merck (Inst); Novartis (Inst); Nuvalent, Inc. (Inst)
 
So Yeon Kim
Consulting or Advisory Role - Boehringer Ingelheim; Genentech; Revolution Medicines
Research Funding - Abbvie (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); Bioinvent (Inst); Boehringer Ingelheim (Inst); Bridgebio (Inst); Bristol Myers Squibb Foundation (Inst); DynamiCure Biotechnology (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); Loxo/Lilly (Inst); MediLink Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Synthekine (Inst); Takeda (Inst); Vaccibody (Inst)
 
Joel Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Johnson & Johnson (I); Rafael Pharmaceuticals; Trumvira
Consulting or Advisory Role - Agenus; ALX Oncology; BeiGene; Boehringer Ingelheim; Cardiff Oncology; Cartography; Civala; Curium Pharma; Fog Pharmaceuticals; Genmab; MBQ Pharma; Merus NV; Revolution Medicines; Urogen pharma; Xilio Therapeutics; Xilio Therapeutics
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Amgen (Inst); Bold Therapeutics (Inst); Camurus (Inst); Cardiff Oncology (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neogene Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Regeneron (Inst); Revolution Medicines (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics
 
Jeffrey Raizer
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Richard Gregory
Employment - Takeda
Stock and Other Ownership Interests - Takeda
Travel, Accommodations, Expenses - Takeda
 
Cierra Casson
Employment - Takeda
Stock and Other Ownership Interests - Takeda
Patents, Royalties, Other Intellectual Property - Patent related to TAK-188 (Inst)
Travel, Accommodations, Expenses - Takeda
 
Deepak Nag Ayyala
Employment - Takeda
 
Amy Sexauer
Employment - Takeda
 
Stephane Champiat
Stock and Other Ownership Interests - Avacta Life Sciences
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai Europe; Fresenius Kabi; Genmab; Janssen; Merck KGaA; Merck Serono; MSD; Novartis; Roche; SERVIER; Takeda
Consulting or Advisory Role - Alderaan Biotechnology; Amgen; AstraZeneca; Avacta Life Sciences; Bayer; BeiGene; BioCodex; BioNTech SE; Boehringer Ingelheim; Celanese; Compugen; Domain Therapeutics; Ellipses Pharma; GE Healthcare; Genmab; Guardant Health; Immunicom; Ipsen; Mariana Oncology; Mima Health; Nanobiotix; NextCure; Oncovita; PharmaMar; Pierre Fabre; Replimune; Seagen; Takeda; Tatum Bioscience; Tollys; UltraHuman8
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Bolt Biotherapeutics; Centessa Pharmaceuticals; Cytovation; Eisai/H3 Biomedicine; Exelixis; GlaxoSmithKline; ImCheck therapeutics; Immunocore; Kumquat Biosciences; Marengo Therapeutics; Molecular Partners; MSD; OncoC4; OSE Immunotherapeutics; Owkin; Pheast Therapeutics; Pierre Fabre; Replimune; Roche/Genentech; Sanofi; Seagen; Sotio; Transgene; Trutino Biosciences; Veracyte (Inst); VIR Biotechnology
Patents, Royalties, Other Intellectual Property - T-cell immunogens derived from anti-viral proteins and methods of using same WO2010039223A2
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GE Healthcare; Merck; MSD; OSE Immunotherapeutics; Roche; Sotio